# Bausch Health Companies Inc. (BHC) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Pharmaceuticals. Price $6.56, market value $2.5 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Bausch Health Companies Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **PEG: 0.00**. A PEG of 0.00 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 0.3×**. Each dollar of revenue is priced at 0.3×, a low multiple typical of thin-margin businesses or out-of-favour stocks.
- **EV / EBITDA: 4.2×**. Enterprise value is 4.2× operating earnings before depreciation, the multiple that ignores how the company is financed; below 8× is inexpensive for most sectors.
- **Free-cash-flow yield: 56.8%** (5-yr avg 14.7%). Free cash flow equals 56.8% of the market value, above its five-year average of 14.7%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.

## Profitability
- **Gross margin: 76.7%**. Bausch Health Companies Inc. keeps 76.7% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 29.0%**. 29.0% of revenue is left after running the business, an exceptional level.
- **Net margin: 1.5%**. 1.5% of each dollar of sales reaches the bottom line.
- **Return on equity: -28.9%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 13.6%**. Return on all capital, debt included, is 13.6%.
- **Return on assets: -4.1%**. Each dollar of assets produces -4.1% of profit.

## Growth
- **Revenue growth (1 yr): 8.5%** (3-yr 8.7%/yr, 5-yr 5.4%/yr). Revenue grew 8.5% over the last year, against 5.4% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 458.3%**. Earnings per share rose 458.3%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Net debt / EBITDA: 3.7×**. It would take 3.7 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Interest coverage: 0.8×**. Operating profit covers interest only 0.8×: fragile.
- **Current ratio: 1.47** (quick 1.08). Current assets cover the next year's liabilities 1.47 times.
- **Altman Z-score: 0.79**. A Z-score of 0.79 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Bausch Health Companies Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: hold** (5 analysts). 5 analysts cover Bausch Health Companies Inc.; the consensus is hold, with an average price target of $7.50 (+14% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -9.0%** (YTD -5.6%, 3-mo 22.2%). The shares are down 9.0% over twelve months including dividends.
- **From 52-week high: -18.0%** (51.5% above the low). Trading 18% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 56**. An RSI of 56 is neutral.
- **Beta (1 yr): 0.85** (volatility 56%). Beta of 0.85 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=BHC · Page: https://foliofundamentals.com/stocks/bhc

Not investment advice.